Neurocrine Biosciences Publishes Clinical Review on Tardive Dyskinesia Treatment with INGREZZA®

Neurocrine Biosciences Advances Understanding of Tardive Dyskinesia Treatment with New Clinical Review

Neurocrine Biosciences, Inc. recently publishes a peer-reviewed narrative review in CNS Spectrums, focusing on the pharmacological and clinical data of VMAT2 inhibitors, particularly INGREZZA® (valbenazine) and deutetrabenazine, for treating tardive dyskinesia. This publication aims to clarify the intricate differences between these two FDA-approved medications, emphasizing INGREZZA's selective targeting of the VMAT2 receptor, which allows for effective therapeutic responses even at the lowest dose of 40 mg. The extensive clinical data supporting INGREZZA across a variety of patient demographics reinforces its position as a vital option for managing tardive dyskinesia.

The review, authored by experts in psychiatry and neurology, delves into significant clinical study results, safety profiles, and dosing considerations, thereby aiding healthcare providers in making informed treatment decisions. It critically highlights that VMAT2 inhibitors are not clinically interchangeable, underscoring the need for a tailored approach to therapy that accounts for each medication’s distinct pharmacologic mechanisms and clinical implications. The differences between INGREZZA and deutetrabenazine are not merely academic; they bear real-world consequences for patient care and treatment outcomes.

Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, emphasizes the importance of this review in guiding healthcare providers toward optimal treatment choices for patients suffering from tardive dyskinesia. The publication serves as an essential resource for clinicians, advocating for a nuanced understanding of VMAT2 inhibitors and reinforcing the distinctive profile of INGREZZA. The review's findings are supported by clinical trials, post-hoc analyses, and long-term studies that collectively affirm the varying dosing requirements and safety profiles of both drugs.

In conjunction with this review, Neurocrine Biosciences continues to prioritize the dissemination of knowledge regarding tardive dyskinesia and its treatment options. By equipping healthcare professionals with comprehensive information about VMAT2 inhibitors, the company aims to enhance patient care and improve treatment outcomes in this challenging therapeutic area.

As the landscape of tardive dyskinesia treatment evolves, publications like this one play a crucial role in shaping best practices and ensuring that patients receive the most effective therapies tailored to their unique needs. Neurocrine’s commitment to advancing clinical understanding is evident in its ongoing efforts to provide high-quality resources for healthcare providers.